The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released ...

FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging, PBMs, UnitedHealth OptumRx, CVS Caremark Rx, Express Scripts ...

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which focuses on pharmacy benefit managers’ influence over specialty generic ...

A new FTC report blames Pharmacy Benefit Managers for marking up specialty drug prices, profiting $7.3 billion from cancer ...

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical ...

Strawberry Hills Pharmacy owner Daniel Jones reacted Thursday to a recent Federal Trade Commission report which showed ...

The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...

I mean, their profits are obscene,” said Hawley. They are both calling on the FTC to release a recent report on pharmacy benefit managers to detail business practices. “They’ve looked at ...